Modern Pediatrics. Ukraine. (2025).8(152): 31-36. doi: 10.15574/SP.2025.8(152).3136
Kurylo H. V.^1,2
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
²Lviv Territorial Medical Association “Multidisciplinary Clinical Hospital of Intensive Care and Emergency Medicine”, Ukraine

For citation: Kurylo HV. (2025). Cholangitis as a factor affecting the effectiveness of treatment of biliary atresia in children. Modern Pediatrics. Ukraine. 8(152): 31-36. doi: 10.15574/SP.2025.8(152).3136.
Article received: Sep 11, 2025. Accepted for publication: Dec 15, 2025.

Biliary atresia (BA) is a severe progressive liver disease in neonates, characterized by obliteration of bile ducts, cholestasis, fibrosis, and cirrhosis. Acute cholangitis (AC) after Kasai hepatoportoenterostomy (KPE) is a key factor influencing treatment efficacy and liver function prognosis.
Aim – to determine diagnostic criteria, assess the effectiveness of treatment, and evaluate the role of interventional procedures in children with BA after KPE.
Materials and methods. Sixty-four children with BA who underwent KPE at 1,5-4,5 months of age were included. AC subtypes were classified by episode frequency: isolated (IAC), early (EAC), recurrent (RAC), and non-resolving (NAC). Treatment included third-generation cephalosporins, combinations with meropenem, co-trimoxazole, and intravenous immunoglobulins. Effectiveness was evaluated by clinical symptoms, laboratory parameters (direct bilirubin, ALT, AST, GGT, CRP, PCT), and instrumental methods. Statistical analysis was performed using the t-test and ANOVA.
Results. AC occurred in 100% of children after KPE. IAC and EAC were characterized by moderate increases in liver enzymes and inflammatory markers and achieved full normalization after third-generation cephalosporin therapy. In RAC patients, combination therapy with meropenem provided rapid normalization of laboratory parameters: direct bilirubin decreased from 78.5±5.3 to 3.1±0.3 µmol/L, CRP from 42,1±1,1 mg/L to 1,1±0.3 mg/L, PCT from 49,7±1,6 ng/mL to 0,9±0,1 ng/mL. In NAC patients, persistent clinical symptoms and elevated inflammatory markers were observed: direct bilirubin 35,9±0,8 µmol/L, CRP 20,6±0.6 mg/L, PCT 12,8±0,5 ng/mL, indicating a severe course and the need for additional interventional and surgical procedures.
Conclusions. AC subtype after KPE determines the severity of clinical and laboratory disturbances and prognosis in children with BA. Differentiated conservative therapy according to AC subtype allows normalization of clinical and laboratory parameters in mild and recurrent forms, whereas severe cases (NAC) require additional interventional procedures. High levels of CRP and PCT are prognostically unfavorable markers of AC severity.
The study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the local ethics committee. Written informed consent was obtained from the children’s legal guardians.
The author declares no conflict of interest.
Keywords: biliary atresia, acute cholangitis, subtypes acute cholangitis, Kasai hepatoportoenterostomy, conservative therapy, antibiotics, immunoglobulins.

REFERENCES

1. Antala S, Taylor SA. (2022). Biliary atresia in children: update on disease mechanisms, therapies, and patient outcomes. Clin Liver Dis. 26: 341-354. https://doi.org/10.1016/j.cld.2022.03.001; PMid:35868678 PMCid:PMC9309872

2. Aziz MA, Abdullatif HM, Soliman MS et al. (2025). A comprehensive clinical and microbiological study on the diagnosis and management of cholangitis in BA patients after Kasai portoenterostomy. Indian J Gastroenterol. 44 (4): 506-516. https://doi.org/10.1007/s12664-024-01721-z; PMid:40072834

3. Calinescu AM, Madadi Sanjani O, Mack C et al. (2022). Cholangitis definition and treatment after Kasai hepatoportoenterostomy for biliary atresia: an international expert panel Delphi consensus. J Clin Med. 11(3): 494. https://doi.org/10.3390/jcm11030494; PMid:35159946 PMCid:PMC8836553

4. Decharun K, Leys CM, West KW et al. (2016). Prophylactic antibiotics for prevention of cholangitis in BA patients status post Kasai portoenterostomy: a systematic review. Clin Pediatr (Phila). 55 (1): 66-72. https://doi.org/10.1177/0009922815594760; PMid:26183324

5. Liu F, Xu X, Wu Y et al. (2024). Alterations of gut microbiota in infants with biliary atresia identified by 16S rRNA-sequencing. BMC Pediatr. 24: 117. https://doi.org/10.1186/s12887-024-04582-9; PMid:38355416 PMCid:PMC10865691

6. Liu F, Xiaogang X, Liang Z et al. (2023). Early bile drainage improves outcomes and impacts cholangitis associated survival after Kasai portoenterostomy. Front Pediatr. 11: 1189792. https://doi.org/10.3389/fped.2023.1189792; PMid:37502192 PMCid:PMC10368976

7. Liu J, Dong R, Chen G et al. (2019). Risk factors and prognostic effects of cholangitis after Kasai procedure in BA patients: a retrospective clinical study. J Pediatr Surg. 54(12): 2559-2564. https://doi.org/10.1016/j.jpedsurg.2019.08.026; PMid:31668401

8. Liu X, Wang Y, Han J et al. (2025). Risk factors for cholangitis after Kasai procedure in biliary atresia patients: a systematic review and meta analysis. Int J Surg. 111: 9726- 9741. https://doi.org/10.1097/JS9.0000000000003227; PMid:40844888 PMCid:PMC12695348

9. Orłowska E, Czubkowski P, Wołochowska K et al. (2021). Assessment of Lactobacillus casei rhamnosus (LGG) therapy in children with biliary atresia – randomized placebo controlled trial. Clin Res Hepatol Gastroenterol. 45(6): 101753. https://doi.org/10.1016/j.clinre.2021.101753; PMid:34311135

10. Shinkai M, Ohhama Y, Take H et al. (2009). Long-term outcome of children with biliary atresia who were not transplanted after the Kasai operation: >20-year experience. J Pediatr Gastroenterol Nutr. 48: 443-450. https://doi.org/10.1097/MPG.0b013e318189f2d5; PMid:19330933